Table 4.

Hazard ratio of all-cause mortality in myocardial infarction and stroke patients.

	Unadjusted HR (95% CI)	p value	Adjusted HR* (95% CI)	p value
Post-MI mortality by prior cancer status among all MI patients
Prior cancer	2.71 (2.56–2.86)	< 0.001	1.48 (1.38–1.59)	< 0.001
No cancer	1.00 (reference)		1.00 (reference)
Post-MI mortality by prior cancer status among MI patients with history of hyperlipidemia
Prior cancer	2.20 (2.04–2.37)	< 0.001	1.34 (1.22–1.47)	< 0.001
No cancer	1.00 (reference)		1.00 (reference)
Post-MI mortality by prior LLT status among MI patients with history of hyperlipidemia
Prior LLT	1.60 (1.52–1.69)	< 0.001	1.05 (0.97–1.14)	0.245
No prior LLT	1.00 (reference)		1.00 (reference)
Post-MI mortality by prior cancer status and prior LLT status among MI patients with history of hyperlipidemia
Prior cancer, no prior LLT	3.47 (2.99–4.03)	< 0.001	1.59 (1.30–1.95)	< 0.001
Prior cancer, prior LLT	3.11 (2.83–3.43)	< 0.001	1.38 (1.21–1.58)	< 0.001
No cancer, prior LLT	1.66 (1.57–1.76)	< 0.001	1.08 (0.99–1.17)	0.080
No cancer, no prior LLT	1.00 (reference)		1.00 (reference)
Post-stroke mortality of cancer status among all stroke patients
Prior cancer	2.27 (2.16–2.38)	< 0.001	1.95 (1.52–2.52)	< 0.001
No cancer	1.00 (reference)		1.00 (reference)

CI confidence interval, HR hazard ratio, LLT lipid lowering therapy, MI myocardial infarction.

*For MI: Adjusted for age at MI, sex, body mass index, smoking, prior treatment for hypertension, prior treatment for diabetes mellitus, LDL-C, left ventricular ejection fraction, ST-segment elevation MI, cardiac arrest, heart failure, and revascularisation.

*For stroke: Adjusted for age at stroke, sex, smoking, history of hypertension, history of diabetes mellitus, history of hyperlipidaemia, history of transient ischaemic attack or stroke, history of ischaemic heart disease, history or newly diagnosed atrial fibrillation or flutter, LDL-C, and baseline National Institutes of Health Stroke Scale score.